TELA Bio, Inc.

1.3200-0.12 (-8.33%)
Oct 29, 4:00:00 PM EDT · NasdaqGM · TELA · USD

Upcoming Earnings

Report date
≈ Nov 6, 2025 (in 7 days)

Key Stats

Market Cap
52.29M
P/E (TTM)
-
Basic EPS (TTM)
-1.06
Dividend Yield
0%

Recent Filings

About

TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

CEO
Mr. Antony Koblish
IPO
11/8/2019
Employees
209
Sector
Healthcare
Industry
Medical Devices